Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR-GPC3 T cells in Lung Squamous Cell Carcinoma
NCT02876978Phase 1Unknown
- Sponsor
- CARsgen Therapeutics
- Start
- Mar 2016
- Primary completion
- Oct 2017
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CT0180 in squamous cell carcinoma of the lung (LSCC), sponsored by CARsgen Therapeutics. Primary endpoint: Occurrence of study related adverse events at 24 weeks. Status: unknown.
02
Drugs
CT0180
03
Conditions
squamous cell carcinoma of the lung (LSCC)
Beyond the preview
Go deeper on NCT02876978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02876978.